充血性心力衰竭患者Lp-PLA2水平对短期预后的影响被引量：3

下载PDF

导出

摘要目的:探讨脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,Lp-PLA2)水平对充血性心力衰竭(CHF)患者短期(90d)临床预后的影响。方法:测定89例CHF患者的Lp-PLA2水平,根据其水平分为高水平组(45例)和低水平组(44例),记录住院期间非致命性心力衰竭及心功能恶化死亡的发生率及随访90d内心血管事件(包括心功能恶化再入院、心力衰竭恶化死亡)的发生率,评价Lp-PLA2水平对CHF患者短期临床预后的影响。结果:在院14d内,非致命性心力衰竭再发患者低水平组5例(11.4%),高水平组12例(26.67%),两组发生率比较差异无统计学意义(χ2=3.37,P>0.05)。心力衰竭恶化死亡低水平组1例(2.3%),高水平组3例(6.7%),两组发生率比较差异均无统计学意义(校正χ2=0.24,P>0.05)。随访90d,低水平组发生心功能恶化再入院7例、心力衰竭恶化死亡2例,总体不良心血管事件9例;高水平组分别为18例、6例、24例。虽然两组因心衰恶化的死亡事件比较差异无统计学意义,但高Lp-PLA2水平组90天内因心功能恶化再入院例数及总体不良心血管事件显著高于低Lp-PLA2水平组。经过Logistic回归分析发现Lp-PLA2的水平可能是影响CHF患者短期(90d)不良心血管事件发生率的一个独立预测因素(P=0.03)。结论:Lp-PLA2可能是评价充血性心力衰竭患者短期预后的独立预测因子。

作者花颖陈楚陆齐

机构地区南通大学附属医院心内科

出处《交通医学》 2015年第6期570-572,共3页 Medical Journal of Communications

基金十二五国家科技支撑计划(2011BAI11B07)

关键词充血性心力衰竭脂蛋白相关磷脂酶A2 短期预后不良心血管事件

分类号 R541.61 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1Mann DL.Inflammatory mediators and the failing heart:past,present,and the foreseeable future[J].Circ Res,2002,91(11):988-998.
2Suzuki T,Solomon C,Jenny NS,et al.Lipoprotein-associated phospholipase A(2)and risk of congestive heart failure in older adults:the Cardiovascular Health Study[J].Circ Heart Fail,2009,2(5):429-436.
3Anand IS,Latini R,Florea VG,et al.C-reactive protein in heart failure:prognostic value and the effect of valsartan[J].Circulation,2005,112(10):1428-1434.
4Khuseyinova N.Koenig W.Predicting the risk of cardiovascular disease:where does lipoprotein-associated phospholipase A2 fit in[J]?Mol Diagn Ther,2007,11(4):203-217.
5李青芳,梁江红,邓胜玲.脂蛋白相关磷脂酶A2与脑梗死患者颈动脉不稳定粥样斑块的关系[J].实用医学杂志,2009,25(2):224-226. 被引量：28
6Yang EH,Mcconnell JP,Lennon RJ,et al.Lipoprotein-associated phospholipase A2 is an Independent marker for coronary endothelial dysfunction in humans[J].Arterioscler Thromb Vasc Biol,2006,26(1):106-111.
7Fischer D,Rossa S,Landmesser U,et al.Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization,cardiac transplantation,or death[J].Eur Heart J,2005,26(1):65-69.
8Gerber Y,Dunlay SM,Jaffe AS,et al.Plasma lipoprotein-associated phospholipase A2 levels in heart failure:association with mortality in the community[J].Atherosclerosis,2009,203(2):593-598.
9Laura C,Kardys I,Bleumink GS,et al.Lipoprotein-associated phospholipase A2 activity and risk of heart failure:The Rotterdam study[J].Eur Heart J,2006,27(19):2346-2352.

二级参考文献9

1European Carotid Surgery Trialists Collaborative Group. Randomised trial of endarterolomy for recently symptomatic carorotic stenosis: final results of the MRC European Carotid Surgery Trial (ECST) [J]. Lancet, 1998, 351 (9113) : 1379-1387.
2Hakkinen T, Luoma J S, Hihunen M O, et al. Lipoproteinassociated phospholioase A2, platelet-activating factor acetylhydrolase,is expressed by macrophages in human and rabbit atheroeclerotic lesions [J]. Arterioscler Thromb Vasc Biol,1999, 19 (12) : 2909-2917.
3Kolodgie F, Burke A, Taye A, et al. Lipoprotein-associated phospholipase A2 is highly expressed in macrophages of epoxyeyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac [J]. Circ Res,2004, 95 (9) : 892-901.
4Leach C A, Hickey D M, Ife R J, et al. Lipoprotein-associated PLA2 inhibition- a novel, nonlipid lowering strategy for atherosclerosis therapy [J]. Farmaeo Jan, 2001,56(1-2) :45-50.
5Virmani R, Burke A P, Farb A, et al. Pathology of the unstable plaque [ J ]. Prog Cardiovasc Dis, 2002,44 (5) : 349-356.
6Forrester J S. Prevention of plaque rupture:a new paradigm of therapy [J]. Ann Intern Med, 2002, 137 (10) : 823-833.
7Conti C R. Updated pathophysiologic concepts in unstable coronary artery disease [J]. Am Heart J,2001,141(2) : 12-14.
8Vinnani R, Burke A P, Farb A, et al. Pathology of the unstable plaque [J]. Prog Cardiovasc Dis, 2002,44 (5) : 349-356.
9Forrester J S. Prevention of plaque rupture:a new paradigm of therapy [ J ]. Ann Intern Med, 2002,137 (10) : 823-833.